Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27560017 | 1.00 | CYP51A1 (0.44) | CYP51A1KMT2AALDH1A1FPR2SMN1; SMN2 | |
| Fumaric Acid SCHEMBL27560048 | 0.95 | CYP51A1 (0.41) | CYP51A1KMT2AALDH1A1FPR2SMN1; SMN2 | |
| Fumaric Acid SCHEMBL6895907 | 0.95 | CYP51A1 (0.41) | CYP51A1KMT2AALDH1A1FPR2SMN1; SMN2 | |
| Fumaric Acid SCHEMBL6895910 | 0.95 | CYP51A1 (0.41) | CYP51A1KMT2AALDH1A1FPR2SMN1; SMN2 | |
| SCHEMBL6897188 | 0.88 | HSD17B10 (0.50) | KMT2AALDH1A1SMN1; SMN2MEN1HSD17B10 | |
| Fumaric Acid SCHEMBL6897338 | 0.84 | CTSL (0.46) | KMT2AALDH1A1SMN1; SMN2MEN1HSD17B10 | |
| Fumaric Acid SCHEMBL6897339 | 0.84 | CTSL (0.46) | KMT2AALDH1A1SMN1; SMN2MEN1HSD17B10 | |
| Fumaric Acid SCHEMBL27541785 | 0.84 | CTSL (0.46) | KMT2AALDH1A1SMN1; SMN2MEN1HSD17B10 | |
| SCHEMBL6897330 | 0.81 | HSD17B10 (0.46) | KMT2AALDH1A1SMN1; SMN2MEN1KDM4E | |
| SCHEMBL6899205 | 0.81 | LPAR1 (0.52) | ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | CYP51A1 2619/4885KMT2A 4759/4885ALDH1A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.